Modular Medical, Inc. is an emerging medical technology company primarily focused on the creation, refinement, and market introduction of insulin pumps. The ...
Modular Medical, Inc. (MODD) is a healthcare/medical-devices company headquartered in San Diego, California. The company’s core mission is to make insulin pump therapy easier to adopt and more broadly accessible for individuals living with diabetes by reducing complexity and lowering the practical barriers to using pump-based insulin delivery systems. Business ...Modular Medical, Inc. (MODD) is a healthcare/medical-devices company headquartered in San Diego, California. The company’s core mission is to make insulin pump therapy easier to adopt and more broadly accessible for individuals living with diabetes by reducing complexity and lowering the practical barriers to using pump-based insulin delivery systems.
Business focus and product direction center on the MODD1 insulin pump platform. The company positions its technology as a way to remove “complicated technology,” enabling a smoother transition for users who may be coming from manual injections. In this context, Modular Medical’s product strategy appears oriented toward usability and adoption: simplifying the user experience and streamlining the path from conventional diabetes management into automated or semi-automated insulin delivery.
From a services/market perspective, as a medical-device developer it typically partners with clinical and regulatory stakeholders and progresses through design refinement, market introduction, and human-use milestones. The materials provided reference the company’s announcement of first human use of MODD1 and describe MODD as a next-generation insulin pump intended for launch.
Cost and affordability are recurring themes. The company states an intent to make higher-quality pump care affordable and easy to use. While specific bill-of-materials (BOM), unit cost targets, or manufacturing economics are not detailed in the provided information, the business rationale is consistent with reducing complexity and effort in the overall system so that the resulting therapy may be offered at a lower effective burden to patients and/or payers.
Financially, the provided dataset indicates the company is still in an investment/transition phase, with negative profitability metrics in trailing-twelve-month measures. That profile is common for development-stage medical technology firms that incur R&D and commercialization costs before achieving sustained revenue and margin expansion.
Key people highlighted in the provided information include CEO James E. Besser (with additional context referencing founder Paul DiPerna as a medical-device professional). Looking forward, the company’s “wishes” and objectives, based on its stated mission, are to liberate and empower the diabetes community through widely usable diabetes technology and to expand access to pump therapy through simplification and affordability.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-28.2M
-50.0%
-1.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-27.7M
-52.0%
+2.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
3.0%
-36.5%
-14.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.03x
-62.3%
-19.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
